Engineering of biocompatible pH-responsive nanovehicles from acetalated cyclodextrins as effective delivery systems for tumor therapy

Journal of Biomedical Nanotechnology

Volumn 11, Issue 6, 2015, Pages 923-941

  Zhang, Dinglin ^a   Wei, Yanling ^b   Chen, Kai ^a   Gong, Hao ^b   Han, Songling ^a   Guo, Jiawei ^a   Li, Xiaohui ^a   Zhang, Jianxiang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Docetaxel; Drug delivery; Nanomedicine; PH Responsive; Tumor therapy; Cyclodextrin

Indexed keywords

BIOCOMPATIBILITY; CELL CULTURE; CYCLODEXTRINS; DRUG DELIVERY; DRUG PRODUCTS; EMULSIFICATION; MEDICAL NANOTECHNOLOGY; SYNTHESIS (CHEMICAL); TUMORS;

ANTI-TUMOR ACTIVITIES; BETA-CYCLODEXTRIN; DOCETAXEL; INTRAVENOUS INJECTIONS; MATERIALS SYNTHESIS; NANOPARTICLE (NPS); PH-RESPONSIVE; TUMOR THERAPY;

BIOLOGICAL MATERIALS;

CYCLODEXTRIN; DOCETAXEL; NANOCARRIER; ACETAL COPOLYMER; ANTINEOPLASTIC AGENT; BETA CYCLODEXTRIN DERIVATIVE; BIOMATERIAL; DRUG CARRIER; NANOPARTICLE; POLYMER; TAXOID;

ACETYLATION; ACUTE TOXICITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCOMPATIBILITY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CANCER SIZE; CELL SURVIVAL; CELL VIABILITY; CHEMICAL STRUCTURE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG EFFICACY; DRUG FORMULATION; DRUG HYDROLYSIS; DRUG PENETRATION; DRUG RELEASE; DRUG UPTAKE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC50; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY INFILTRATE; MALE; MELANOMA; MOUSE; MULTIDRUG RESISTANCE; NANOEMULSION; NANOENGINEERING; NANOFABRICATION; NANOMEDICINE; NONHUMAN; ONE POT SYNTHESIS; PH; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION TIME; SCANNING ELECTRON MICROSCOPY; SINGLE DRUG DOSE; STEREOSPECIFICITY; TOXICITY TESTING; TRANSMISSION ELECTRON MICROSCOPY; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CHEMISTRY; HEPG2 CELL LINE; METABOLISM; NEOPLASMS; NUDE MOUSE; PROCEDURES; SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; BETA-CYCLODEXTRINS; BIOCOMPATIBLE MATERIALS; CELLS, CULTURED; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HEP G2 CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; NEOPLASMS; POLYMERS; TAXOIDS;

EID: 84918564750     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2015.2009     Document Type: Article

References (54)

1. K. Miyata, N. Nishiyama, and K. Kataoka, Rational design of smart supramolecular assemblies for gene delivery: Chemical challenges in the creation of artificial viruses. Chem. Soc. Rev. 41, 2562 (2012).
2. B. P. Timko, K. Whitehead, W. W. Gao, D. S. Kohane, O. Farokhzad, D. Anderson, and R. Langer, Advances in drug delivery. Annu. Rev. Mater. Res. 41, 1 (2011).
3. R. de la Rica, D. Aili, and M. M. Stevens, Enzyme-responsive nanoparticles for drug release and diagnostics. Adv. Drug Deliv. Rev. 64, 967 (2012).
4. R. Lehner, X. Y. Wang, M. Wolf, and P. Hunziker, Designing switchable nanosystems for medical application. J. Control Release 161, 307 (2012).
5. J. M. Morachis, E. A. Mahmoud, and A. Almutairi, Physical and chemical strategies for therapeutic delivery by using polymeric nanoparticles. Pharmacol. Rev. 64, 505 (2012).
6. Y. P. Wang, J. D. Byrne, M. E. Napier, and J. M. DeSimone, Engineering nanomedicines using stimuli-responsive biomaterials. Adv. Drug Deliv. Rev. 64, 1021 (2012).
7. J. X. Zhang, X. D. Li, and X. H. Li, Stimuli-triggered structural engineering of synthetic and biological polymeric assemblies. Prog. Polym. Sci. 37, 1130 (2012).
8. K. Sampathkumar, S. Arulkumar, and M. Ramalingam, Advances in stimuli responsive nanobiomaterials for cancer therapy. J. Biomed. Nanotechnol. 10, 367 (2014).
9. W. W. Gao, J. M. Chan, and O. C. Farokhzad, pH-responsive nanoparticles for drug delivery. Mol. Pharmaceutics 7, 1913 (2010).
10. S. Manchun, C. R. Dass, and P. Sriamornsak, Targeted therapy for cancer using pH-responsive nanocarrier systems. Life Sci. 90, 381 (2012).
11. H. W. Sung, K. Sonaje, Z. X. Liao, L. W. Hsu, and E. Y. Chuang, pH-Responsive nanoparticles shelled with chitosan for oral delivery of insulin: From mechanism to therapeutic applications. Accounts Chem. Res. 45, 619 (2012).
12. X. Q. Wang and Q. Zhang, pH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide/protein drugs and poorly water-soluble drugs. Eur. J. Pharm. Biopharm. 82, 219 (2012).
13. E. S. Lee, Z. G. Gao, and Y. H. Bae, Recent progress in tumor pH targeting nanotechnology. J. Control Release 132, 164 (2008).
14. P. Prabhu and V. Patravale, The upcoming field of theranostic nanomedicine: An overview. J. Biomed. Nanotechnol. 8, 859 (2012).
15. J. X. Zhang, M. Q. Yan, X. H. Li, L. Y. Qiu, X. D. Li, X. J. Li, Y. Jin, and K. J. Zhu, Local delivery of indomethacin to arthritis-bearing rats through polymeric micelles based on amphiphilic polyphosphazenes. Pharm. Res. 24, 1944 (2007).
16. C. A. Hunt, R. D. MacGregor, and R. A. Siegel, Engineering targeted in vivo drug delivery. 1. The physiological and physicochemical principles governing opportunities and limitations. Pharm. Res. 3, 333 (1986).
17. S. Ganta, H. Devalapally, A. Shahiwala, and M. Amiji, A review of stimuli-responsive nanocarriers for drug and gene delivery. J. Control Release 126, 187 (2008).
18. K. A. Whitehead, R. Langer, and D. G. Anderson, Knocking down barriers: Advances in siRNA delivery. Nat. Rev. Drug Discov. 8, 129 (2009).
19. F. H. Meng, R. Cheng, C. Deng, and Z. Y. Zhong, Intracellular drug release nanosystems. Mater. Today 15, 436 (2012).
20. J. H. Jeong, S. W. Kim, and T. G. Park, Novel intracellular delivery system of antisense oligonucleotide by self-assembled hybrid micelles composed of DNA/PEG conjugate and cationic fusogenic peptide. Bioconjugate Chem. 14, 473 (2003).
21. Y. Bae, S. Fukushima, A. Harada, and K. Kataoka, Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: Polymeric micelles that are responsive to intracellular pH change. Angew. Chem. Int. Ed. 42, 4640 (2003).
22. E. M. Bachelder, T. T. Beaudette, K. E. Broaders, J. Dashe, and J. M. J. Frechet, Acetal-derivatized dextran: An acid-responsive biodegradable material for therapeutic applications. J. Am. Chem. Soc. 130, 10494 (2008).
23. Y. Lee, K. Miyata, M. Oba, T. Ishii, S. Fukushima, M. Han, H. Koyama, N. Nishiyama, and K. Kataoka, Charge-conversion ternary polyplex with endosome disruption moiety: A technique for efficient and safe gene delivery. Angew. Chem. Int. Ed. 47, 5163 (2008).
24. M. C. Parrott, J. C. Luft, J. D. Byrne, J. H. Fain, M. E. Napier, and J. M. DeSimone, Tunable bifunctional silyl ether cross-linkers for the design of acid-sensitive biomaterials. J. Am. Chem. Soc. 132, 17928 (2010).
25. M. Ali, M. Oishi, F. Nagatsugi, K. Mori, Y. Nagasaki, K. Kataoka, and S. Sasaki, Intracellular inducible alkylation system that exhibits antisense effects with greater potency and selectivity than the natural oligonucleotide. Angew. Chem. Int. Ed. 45, 3136 (2006).
26. J. Cao, S. Y. Zhai, C. L. Li, B. He, Y. S. Lai, Y. W. Chen, X. L. Luo, and Z. W. Gu, Novel pH-sensitive micelles generated by star-shape copolymers containing zwitterionic sulfobetaine for efficient cellular internalization. J. Biomed. Nanotechnol. 9, 1847 (2013).
27. V. J. Venditto and F. C. Szoka, Cancer nanomedicines: So many papers and so few drugs. Adv. Drug Deliv. Rev. 65, 80 (2013).
28. J. J. Shi, Z. Y. Xiao, N. Kamaly, and O. C. Farokhzad, Selfassembled targeted nanoparticles: Evolution of technologies and bench to bedside translation. Accounts Chem. Res. 44, 1123 (2011).
29. R. Duncan and R. Gaspar, Nanomedicine(s) under the microscope. Mol. Pharmaceutics 8, 2101 (2011).
30. Z. L. Cheng, A. A. Zaki, J. Z. Hui, V. R. Muzykantov, and A. Tsourkas, Multifunctional nanoparticles: Cost versus benefit of adding targeting and imaging capabilities. Science 338, 903 (2012).
31. S. Lee, S. C. Yang, M. J. Heffernan, W. R. Taylor, and N. Murthy, Polyketal microparticles: A new delivery vehicle for superoxide dismutase. Bioconjugate Chem. 18, 4 (2007).
32. K. E. Broaders, J. A. Cohen, T. T. Beaudette, E. M. Bachelder, and J. M. J. Frechet, Acetalated dextran is a chemically and biologically tunable material for particulate immunotherapy. PNAS 106, 5497 (2009).
33. H. Morinaga, H. Morikawa, Y. Wang, A. Sudo, and T. Endo, Amphiphilic copolymer having acid-labile acetal in the side chain as a hydrophobe: Controlled release of aldehyde by thermoresponsive aggregation-dissociation of polymer micelles. Macromolecules 42, 2229 (2009).
34. A. P. Griset, J. Walpole, R. Liu, A. Gaffey, Y. L. Colson, and M. W. Grinstaff, Expansile nanoparticles: Synthesis, characterization, and in vivo efficacy of an acid-responsive polymeric drug delivery system. J. Am. Chem. Soc. 131, 2469 (2009).
35. J. X. Zhang, Y. Jia, X. D. Li, Y. Q. Hu, and X. H. Li, Facile engineering of biocompatible materials with pH-modulated degradability. Adv. Mater. 23, 3035 (2011).
36. M. E. Davis and M. E. Brewster, Cyclodextrin-based pharmaceutics: Past, present and future. Nat. Rev. Drug Discov. 3, 1023 (2004).
37. J. X. Zhang and P. X. Ma, Host-guest interactions mediated nanoassemblies using cyclodextrin-containing hydrophilic polymers and their biomedical applications. Nano Today 5, 337 (2010).
38. J. X. Zhang and P. X. Ma, Cyclodextrin-based supramolecular systems for drug delivery: Recent progress and future perspective. Adv. Drug Deliv. Rev. 65, 1215 (2013).
39. E. Bilensoy, Nanoparticulate delivery systems based on amphiphilic cyclodextrins. J. Biomed. Nanotechnol. 4, 293 (2008).
40. M. E. Davis, J. E. Zuckerman, C. H. J. Choi, D. Seligson, A. Tolcher, C. A. Alabi, Y. Yen, J. D. Heidel, and A. Ribas, Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067 (2010).
41. J. Li and X. J. Loh, Cyclodextrin-based supramolecular architectures: Syntheses, structures, and applications for drug and gene delivery. Adv. Drug Deliv. Rev. 60, 1000 (2008).
42. M. E. Davis, Design and development of IT-101, a cyclodextrincontaining polymer conjugate of camptothecin. Adv. Drug Deliv. Rev. 61, 1189 (2009).
43. H. P. Chen, X. P. Liu, Y. Dou, B. F. He, L. Liu, Z. H.Wei, J. Li, C. Z. Wang, C. D. Mao, J. X. Zhang, and G. S. Wang, A pH-responsive cyclodextrin-based hybrid nanosystem as a nonviral vector for gene delivery. Biomaterials 34, 4159 (2013).
44. H. M. He, S. Chen, J. Z. Zhou, Y. Dou, L. Song, L. Che, X. Zhou, X. Chen, Y. Jia, J. X. Zhang, S. H. Li, and X. H. Li, Cyclodextrin-derived pH-responsive nanoparticles for delivery of paclitaxel. Biomaterials 34, 5344 (2013).
45. X. P. Liu, G. S. Wang, Z. C. You, P. Qian, H. P. Chen, Y. Dou, Z. H. Wei, Y. Chen, C. D. Mao, and J. X. Zhang, Inhibition of hypoxiainduced proliferation of pulmonary arterial smooth muscle cells by a mTOR siRNA-loaded cyclodextrin nanovector. Biomaterials 35, 4401 (2014).
46. T. H. Fife and L. K. Jao, Substituent effects in acetal hydrolysis. J. Org. Chem. 30, 1492 (1965).
47. S. M. Moghimi, A. C. Hunter, and J. C. Murray, Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol. Rev. 53, 283 (2001).
48. D. W. Frank, J. E. Gray, and R. N. Weaver, Cyclodextrin nephrosis in the rat. Am. J. Pathol. 83, 367 (1976).
49. J. Hrkach, D. Von Hoff, M. M. Ali, E. Andrianova, J. Auer, T. Campbell, D. De Witt, M. Figa, M. Figueiredo, A. Horhota, S. Low, K. McDonnell, E. Peeke, B. Retnarajan, A. Sabnis, E. Schnipper, J. J. Song, Y. H. Song, J. Summa, D. Tompsett, G. Troiano, T. V. Hoven, J. Wright, P. LoRusso, P. W. Kantoff, N. H. Bander, C. Sweeney, O. C. Farokhzad, R. Langer, and S. Zale, Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med. 4, 128ra39 (2012).
50. G. Sahay, D. Alakhova, and A. V. Kabanov, Endocytosis of nanomedicines. J. Control Release 145, 182 (2010).
51. J. Fang, H. Nakamura, and H. Maeda, The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 63, 136 (2011).
52. F. Alexis, E. Pridgen, L. K. Molnar, and O. C. Farokhzad, Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharmaceutics 5, 505 (2008).
53. M. E. Davis, Z. Chen, and D. M. Shin, Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7, 771 (2008).
54. N. Kamaly, Z. Xiao, P. M. Valencia, A. F. Radovic-Moreno, and O. C. Farokhzad, Targeted polymeric therapeutic nanoparticles: Design, development and clinical translation. Chem. Soc. Rev. 41, 2971 (2012).